Finoriq research workspace
Ascendis Pharma A/S (ASND) Historical Metrics
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based. Review ASND valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
- Company
- Ascendis Pharma A/S (ASND)
- Ticker
- ASND
- Market Cap
- $15.7B
- Latest Price
- $252.88
- Industry
- Biotech & Pharma
Ascendis Pharma A/S (ASND) Current Valuation Metrics
Static valuation preview for Ascendis Pharma A/S (ASND). Market data retrieved 2026-07-08. Filing currency EUR.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 20.7x | Revenue | TTM FY 2025 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 276x | Operating Cash Flow | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -1.5% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 0.36% | Operating Cash Flow | TTM FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.